Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Cognition Therapeutics, Inc. (NASDAQ:CGTX) is one of the most popular penny stocks on Robinhood.

TheFly reported on May 21 that CGTX held a planned regulatory meeting with the U.S. Food and Drug Administration to review Phase 2 results for zervimesine and discuss the framework for a future registrational study in dementia with Lewy bodies accompanied by psychosis. The discussion focused on clinical outcomes from the COG1201 “SHIMMER” trial and potential endpoints for advancing the program into later-stage development. Management described the meeting as productive and indicated that both parties reviewed the proposed path toward a registrational pathway for zervimesine in DLB-related psychosis. The company expects to receive formal meeting minutes in June, which will further clarify regulatory guidance and next steps for advancing the therapeutic program into pivotal-stage planning and continued clinical development activities.

Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?

Separately, Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its first-quarter 2026 financial results on May 7, 2026, covering the period ended March 31, 2026. The company reported a net loss of $4.6 million, or $0.05 per share, compared with $8.5 million, or $0.14 per share, in the prior year period. Operating costs declined year over year, with research and development expenses falling to $6.1 million from $10.8 million due to reduced clinical trial activity and lower external research spending. General and administrative expenses also decreased to $2.7 million from $3.0 million, driven by lower compensation and stock-based costs. As of March 31, 2026, Cognition held approximately $31.2 million in cash and equivalents, along with $25.6 million in remaining grant funding, supporting projected operations into the second quarter of 2027.

Cognition Therapeutics, Inc. (NASDAQ:CGTX) is a clinical-stage biotech company developing oral small-molecule therapies aimed at protecting neuronal synapses to slow or stop neurodegenerative and retinal diseases.

While we acknowledge the risk and potential of CGTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CGTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1